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Introduction
Epidermal growth factor receptor (EGFR), an essential mediator for various growth factors, plays a pivotal role in regulating cell proliferation, migration, and cell cycle progression through activation of distinct signaling pathways. ?osttranslational modifications of EGFR such as phosphorylation, ubiquitination, and neddylation confer EGFR a multipotent player and arbitrate the fate of EGFR in mediating signal transduction, subcellular localiBation, or protein degradation (1). Cpon Ligand binding, EGFR dimeriBes, autophosphorylates, and trigger a myriad of downstream signaling, such as the activation of phosphoinositide 3 kinase-protein kinase B (?I3K-?KB/AKT), mitogen-activated protein kinase (MA?K), Oak/the signal transducers and activators of transcription (STAT), Rho family GT?ase (QAQ2), and ?hospholipase C (?LC") (2) . These signaling activities regulate cell proliferation, mobility, and differentiation in many different cell types. To date, tyrosine phosphorylation of EGFR is relatively well characteriBed and most of them respond to ligand stimulation. For example, U8WX (Tyr8WX) phosphorylation by c-Src is implicated in stabiliBing the activation loop, maintaining the enByme activity and providing a binding surface for the STATXb (3) (4). UYY2 is a direct binding site for the ?LC! SZ2 domain, resulting in activation of ?LC!-mediated downstream signaling (5) . U1[WX phosphorylation creates a ma\or docking site for c-Cbl, an ubiquitin E3 ligase, leads to receptor ubiquitination and degradation.
U1[]8 phosphorylation recruits Grb2 (6), whereas U11W8 and U11^3 provide a docking site for SZC binding (4). Except for extensive knowledge on tyrosine phosphorylation, serine and threonine phosphorylation of EGFR is less understood, and they usually related to negatively regulation of EGFR. For example, the S1[W]
and S1[W^ phosphorylation by CaM kinase II attenuates EGFR kinase activity, and mutation of either of them enhances EGFR kinase activity (7).
In this proposal, we found a ma\or inflammation regulator, IKK!, potentially inhibits EGFR activity through a novel signaling pathway in breast cancer cells. IKK!#directly interacted with and phosphorylated EGFR at S1 [2] . Inhibition of IKK activity led to hyperphosphorylaiton of EGFR U8WX and STAT3. Therefore, we hypothesiBed that IKK! phosphorylates EGFR resulting in a functional inactivation of EGFR at U8WX, thereby inactivating STAT3 activity. To understand the underlying mechanism of EGFR regulation, various inhibitors were selected and tested their effect on EGFR tyrosine phosphorylation using an anti phospho-tyrosine antibody (WG1[) ( Fig. 2A ). Among all tested inhibitors, Bay 11-^[82 (Calbiochem), an IKK kinase inhibitor, unexpectedly enhance EGFR tyrosine phosphorylation in the presence of 2X ng/ml EGF treatment ( Fig. 2B ). To determine the tyrosine residue might respond to the EGFR activation, six well known anti phospho-tyrosine antibodies of EGFR (pTyr8WX, pTyrYY2, pTyr1[8] , pTyr11W8, and pTyr11^3) were also examined. We found that Bay 11-^[82 drastically enhances Tyr8WX activation, whereas others remain virtually no activation in MDA-MB-W]8 cells ( Fig. 2C ). We also examine the activation of EGFR downstream targets ?LC"$#%pTyr&'(), QAQ2 (pTyr1^2), STAT3
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(pTyr^[X), AKT (pSerW^[), and ERK (pTyr2[W) in the presence of Bay 11-^[82 treatment. Surprisingly, inhibition of IKK results in specific activation of EGFR Tyr8WX and STAT3 Tyr^[X (Fig. 2C ). To exclude out the off-target effect using chemical inhibitors, we used siRaA to knockdown IKK!##and!#*++, expression.
Consistent with our earlier finding, downregulation of IKK! elevates EGFR Tyr8WX phosphorylation and p-STAT3 status, supporting the notion that EGFR activity is negatively regulated by IKK!.
IKK! Physically Interacts with EGFR
bur finding that inhibition of IKK activates EGFR signaling prompted us to investigate the mechanism by which IKK mediated downregulation of EGFR. Since the IKK complexes are the upstream molecules responsible for the regulation of aF-B activity, we investigated whether the regulation of EGFR by aF-B pathway via IKK complex (IKK!, IKK,, and IKK"). To do so, ZEK 2Y3 cells were transiently transfected with EGFR together with Flagged-IKK!, IKK,, and IKK". Coimmunoprecipitation (Co-I?) experiments showed that IKK! but not *++, or *++" physically associates with EGFR ( Fig. 3A) . Similar results were confirmed using a reverse I? (Fig. 3B ). The specific interaction between IKK! and EGFR was also observed at endogenous level in MDA-MB-W]8 cells using specific antibodies against IKK! and EGFR ( Fig. 3C ). To test the direct physical interaction, an in vitro GST pull down assay was conducted and identified EGFR preferentially interacts with IKK! a-terminal domain (Fig. 3D ). In addition to their physical interaction, cellular fractionation assay reveals that both IKK! and EGFR colocaliBed in the Golgi apparatus under EGF stimulation ( Fig. 3E ). Since EGFR undergo ligand dependent internaliBation, we hypothesis the physical contact of EGFR and IKK! appears at Golgi apparatus.
Given the physical association between IKK! and EGFR, we examined whether EGFR is a physiological substrate of IKK!. To test this hypothesis, EGFR together with IKK!, nIKK! (dominant negative), K1WWM (kinase dead) and *++, were overexpressed in ZEK 2Y3 cells and sub\ected to I? of EGFR. We found that IKK! catalyBed EGFR serine phosphorylation using an anti-phosphoserine antibody ( Fig. WA) and treatment with Bay 11-^[82 abrogates this phosphorylation (Fig. WB) . Since IKK!/, activates one another in the transient transfection system, we utiliBed an in vitro kinase assay in the following experiment. We found that the EGFR C-terminal domain (CR, Y^8 aa-1211 aa) was strongly phosphorylated by IKK!, whereas other domains (OM, aa ]X[-^18 and KD, aa ^18-Y^8) were not ( Fig. WC and WD) . Although S]]YA and SY^]A of EGFR complete abolishes ?38 MA?K phosphorylation, they do not affect IKK! mediated EGFR phosphorylation. To identify the IKK! mediated EGFR phosphorylation, mass spectrometry analysis of in vitro kinase assay reveals that EGFR Ser1 [2] is phosphorylated by IKK! (Fig. WE) . Mutation of Ser residue into Ala (S1 [2] A) abolished the phosphorylation by IKK! but not other known phosphorylation sites ( Fig. WF) , suggesting that IKK! directly phosphorylates EGFR at S1 [2] . To assess whether this phosphorylation occurs in vivo, mass spectrometry analysis was performed and confirmed EGFR S1 [2] phosphorylation in MDA-MB-W]8 cells (data not shown).
Characterize the Biological Activity of EGFR S1026A
The biological activities of IKK! mediated EGFR S1 [2] phosphorylation was vigorously achieved. As proposed in the specific Aim 1, we established EGFR stable transfectants with EQ (empty vector), EGFR wild type, EGFR Da (dominant negative, D83^A), a well-known patient mutation (L8X8R) and S1 [2] A in aIZ3T3, CZb and MCF^ breast cancer cell lines, in which the basal level of EGFR is low. In fact, the functional analysis of EGFR utiliBing these cells for various purposes has been well established in our lab. Therefore, these cell lines served as good recipients for establishing stable transfectants of EGFR and its variants. To create EGFR stable clones, replication incompetent retroviruses produced from pBABE-puro-EGFR vectors by cotransfection in the ZEK 2Y3 phoenix packaging cell line (Clontech). Cells were then selected using 2 .g/.l puromycin for 1[ days to remove low-or non-infected cells. To rule out the possibility that protein conformational misfolding may occur by amino acid substitution, we analyBed membrane associated EGFR ( bound EGFR are similar in all stable clones compared to the cells infected with empty vector, suggesting that mutation of EGFR does not influence its cellular property.
To investigate the activation of EGFR signaling, EGFR stable transfectants were serum-starved overnight and treated with 2X ng/ml for various time points. Indeed, EGFR WT activated a good induction of p-STAT3, p-AKT, or p-Erk in response to EGF treatment, whereas EGFR Da failed to do so. Consistent with our hypothesis, EGFR S1 [2] A showed a higher activation of Tyr8WX and p-STAT3 with similar degree to that of EGFR L8X8R.
In fact, EGFR S1 [2] A mediated hyperactivation is specific, because p-AKT and p-Erk status did not change compared with EGFR WT (Fig. XB) .
The Functionality of EGFR S1026A
To test the biological behavior of EGFR S1 [2] A, a 3-(W,X-dimethylthiaBol-2-yl)-2,X-diphenyltetraBolium bromide (MTT) colorimetric assays was performed. We observed that MCF^-EGFR (S1[2]A) cells grew more quickly than MCF^-EGFR (WT) cells, whereas MCF^-EGFR Da showed a reduced growth (Fig. ] ).
Figure 5. EGFR S0126A exhibits hyperactivation in p-EGFR Y845 and p-STAT3.
(A) aIZ3T3 stable clones carry various EGFR variants were sub\ected to FACS analysis to identified their membrane EGFR localiBation. As wild type aIZ3T3 cells harbor low EGFR expression, the EGFR variants stable clones showed similar expression and localiBation. (B) EGFR S1 [2] A shows hyperactivation of U8WX and p-STAT3. EGFR Stable clones were serum starved for overnight and treated with 3[ng/ul EGF at indicated time points. EGFR tyrosine phosphorylation and its downstream signaling were analyBed by Western blot. Figure 6 . EGFR S1026A associates with more aggressive phenotype. In vitro cell proliferation rate were assayed using MTT colorimetric method. Compared with Empty vector, EGFR WT and dominant negative (Da), EGFR S1 [2] A showed a enhanced cell proliferation.
Since EGFR also regulates cellular migration and invasion, we also observed a significant increase of cell migration in MCF^-EGFR S1 [2] A in compared with MCF^-EGFR WT (data not shown). As we proposed in the sub-aim 1, orthotropic breast cancer mouse model analyBing tumorigenesis of EGFR S1 [2] A has recently been initiated. A total of 8[ mice carrying MCF^-EQ, MCF^-EGFR WT, EGFR Da and EGFR (S1 [2] A) were established via mammary fat pad in\ection to measure the impact of EGFR S1 [2] A on cells proliferation in vivo.
This part of study is currently ongoing and the result will be presented in the next annual report.
Consistently, IKK! deficient MEF cells specifically upregulated EGF-induced Tyr 8WX phosphorylation and p-STAT3 status (Fig. ^A) . In addition, stably overexpression of IKK! KD (Kinase dead) and IKK! CA (constitutive activated) in MDA-MB-W]8 cells showed lower EGFR p-U8WX and p-STAT3 status (Fig. ^B) .
These results indicate that IKK! inhibits EGFR activity by suppressing EGFR U8WX phosphorylation and STAT3 activity.
Future Works
To determine this IKK!/EGFR/STAT3 signaling axis occur in vivo, we proposed to generate transgenic mice using current available strain. In the following year, we will generate a conditional knockout mouse model of IKK! in the mammary gland (IKK! F/F MMTQ-Cre, deleted in mammary gland) by crossing IKK!-floxed mice with the MMTQ-Cre mice that express Cre recombinase under the control of the mouse mammary tumor virus promoter (MMTQ-Cre), which is exclusively expressed in the mammary gland. The IKK! F/F MMTQ-Cre mammary gland specific knockout mice may not develop physically palpable or microscopically observable mammary tumors. Because the tumor suppressor function of IKK!#is exclusively via its phosphorylaiton of EGFR, we will cross IKK! F/d MMTQ-Cre mice with IKK! F/d MMTQ-EGFR to see if the phenotype could be enhanced in the conditional knockoout-transgenic mice. Mice tumor section will be stained with EGFR S1 [2] antibody. Downstream signaling such as p-EGFR 8WX and p-STAT3 will also be included to test our hypothesis.
Key Research Accomplishments 2010-2011
CharacteriBe the biological activity of EGFR S1 [2] A and S1[2]D a) Generate EGFR WT, Da, S1[2]A, S1 [2] D constructs in the retroviral vector (pBABE) to produce viruses in ZEK2Y3 phoenix cells. (All constructs have been restriction mapped and confirmed by full-length sequencing) b) Establish EGFR S1 [2] A stable cell line in breast cancer cells that harbor low or no EGFR expression. To achieve this aim, aIZ3T3, Cho and MCF^ cells were selected as recipients for retrovirus infection. Cells are now stabiliBed in 2 .g/.l puromycin with equal level of EGFR expression ( Fig. X) . aIZ3T3 and Cho stable cells are used for signaling and molecular studies, whereas MCF^ cells are used for tumorigenesis for mammary fat pad in\ection. c) Investigate the impact of EGFR S1 [2] A in regulating EGFR U8WX and p-STAT3 phosphorylation. As shown in Figure W , EGFR S1 [2] A show an elevated phosphorylation of p-U8WX and p-STAT3. d) Investigate the biological function of EGFR S1 [2] in vitro using soft agar assay and MTT cell proliferation assay. EGFR S1 [2] A shows more malignant nature in cell proliferation assay and anchorage independent assay.
